Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Balar AV"'
Autor:
Balar, Arjun V, Galsky, Matthew D, Rosenberg, Jonathan E, Powles, Thomas, Petrylak, Daniel P, Bellmunt, Joaquim, Loriot, Yohann, Necchi, Andrea, Hoffman-Censits, Jean, Perez-Gracia, Jose Luis, Dawson, Nancy A, van der Heijden, Michiel S, Dreicer, Robert, Srinivas, Sandy, Retz, Margitta M, Joseph, Richard W, Drakaki, Alexandra, Vaishampayan, Ulka N, Sridhar, Srikala S, Quinn, David I, Durán, Ignacio, Shaffer, David R, Eigl, Bernhard J, Grivas, Petros D, Yu, Evan Y, Li, Shi, Kadel, Edward E, Boyd, Zachary, Bourgon, Richard, Hegde, Priti S, Mariathasan, Sanjeev, Thåström, AnnChristine, Abidoye, Oyewale O, Fine, Gregg D, Bajorin, Dean F, IMvigor210 Study Group
Summary Background First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8a6a5d4e1d8b7a8b214348187af3dbd
https://hdl.handle.net/10668/10669
https://hdl.handle.net/10668/10669
Autor:
Thomas Powles, Petros Grivas, Ani Balmanoukian, Jose Luis Perez-Gracia, Dean F. Bajorin, Richard W. Joseph, Oyewale O. Abidoye, Christina Canil, Daniel Castellano, Na Cui, Sanjeev Mariathasan, Michiel S. van der Heijden, Richard Bourgon, Mark D. Fleming, Peter H. O'Donnell, Andrea Necchi, Yohann Loriot, Garrett M. Frampton, Nancy A. Dawson, Dorothee Nickles, Jonathan E. Rosenberg, Robert Dreicer, Daniel P. Petrylak, Arjun Vasant Balar, Joaquim Bellmunt, Margitta Retz, Jean H. Hoffman-Censits, Howard A. Burris, Sandy Srinivas, Matthew D. Galsky, Gregg Fine
Background Patients with metastatic urothelial carcinoma have few treatment options after failure of platinum-based chemotherapy. In this trial, we assessed treatment with atezolizumab, an engineered humanised immunoglobulin G1 monoclonal antibody th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f588e849690c67a46f661dc9f07abf0
Autor:
Loriot Y; Institut de Cancérologie Gustave Roussy, Villejuif, France., Balar AV; Perlmutter Cancer Center at NYU Langone Health, New York, New York., Petrylak DP; Smilow Cancer Center, Yale School of Medicine, New Haven, Connecticut., Kalebasty AR; University of California Irvine, Irvine, California., Grivas P; Fred Hutchinson Cancer Center, University of Washington, Seattle, Washington., Fléchon A; Centre Léon Bérard, Lyon, France., Jain RK; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Swami U; Huntsman Cancer Hospital, Salt Lake City, Utah., Bupathi M; Rocky Mountain Cancer Centers, Littleton, Colorado., Barthélémy P; Hôpitaux Universitaires de Strasbourg, Institut de Cancérologie Strasbourg Europe, Strasbourg, France., Beuzeboc P; Hôpital Foch, Suresnes, France., Palmbos P; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan., Kyriakopoulos CE; University of Wisconsin Carbone Cancer Center, Madison, Wisconsin., Pouessel D; Institut Claudius Regaud/IUCT-Oncopole, Toulouse, France., Sternberg CN; Weill Cornell Medicine, New York, New York., Tonelli J; Gilead Sciences, Inc., Parsippany, New Jersey., Sierecki M; Gilead Sciences, Inc, Foster City, California., Zavodovskaya M; Gilead Sciences, Inc, Foster City, California., Elboudwarej E; Gilead Sciences, Inc, Foster City, California., Diehl L; Gilead Sciences, Inc, Foster City, California., Jürgensmeier JM; Gilead Sciences, Inc, Foster City, California., Tagawa ST; Weill Cornell Medicine, New York, New York.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Aug 01; Vol. 30 (15), pp. 3179-3188.
Autor:
Necchi A; Vita-Salute San Raffaele University Milan, Milan, Italy. necchi.andrea@hsr.it.; Department of Medical Oncology, IRCCS San Raffaele Hospital and Scientific Institute, Via Olgettina 60, 20132, Milan, Italy. necchi.andrea@hsr.it., Van der Heijden MS; The Netherlands Cancer Institute, Amsterdam, Netherlands., Trukhin D; Odessa Regional Oncological Dispensary, Odessa, Ukraine., Peer A; Rambam Health Care Center, Haifa, Israel., Gurney H; Macquarie University, Sydney, Australia., Alekseev BY; PA Hertsen Moscow Cancer Research Institute, Moscow, Russia., Parnis FX; Adelaide Cancer Centre, Kurralta Park, Australia.; University of Adelaide, Adelaide, Australia., Leibowitz R; Oncology Institute, Shamir Medical Center, Be'er yaakov, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., De Santis M; Department of Urology, Charité Universitätsmedizin, Berlin, Germany.; Medical University Vienna, Wien, Austria., Grivas P; University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Clark J; Incyte Corporation, Wilmington, Delaware, USA., Munteanu M; Incyte Corporation, Wilmington, Delaware, USA., Kataria R; Merck & Co., Inc., Rahway, NJ, USA., Jia C; Merck & Co., Inc., Rahway, NJ, USA., Balar AV; Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY, USA., de Wit R; Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands.
Publikováno v:
BMC cancer [BMC Cancer] 2024 Jul 25; Vol. 23 (Suppl 1), pp. 1252. Date of Electronic Publication: 2024 Jul 25.
Autor:
Loriot Y; Medical Oncology Department, Institut de Cancérologie Gustave Roussy, Université Paris-Saclay, Villejuif, France. Electronic address: Yohann.LORIOT@gustaveroussy.fr., Petrylak DP; Genitourinary Oncology, Yale School of Medicine, New Haven., Rezazadeh Kalebasty A; School of Medicine, University of California Irvine, Irvine, USA., Fléchon A; Department of Medical Oncology, Centre Léon Bérard, Lyon, France., Jain RK; Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa., Gupta S; Division of Oncology, Department of Medicine, Huntsman Cancer Institute, Salt Lake City., Bupathi M; Medical Oncology, Rocky Mountain Cancer Centers, Littleton, USA., Beuzeboc P; Oncology and Supportive Care Department, Hôpital Foch, Suresnes, France., Palmbos P; Urologic Oncology Clinic, Rogel Cancer Center, University of Michigan, Ann Arbor., Balar AV; Genitourinary Oncology Department, New York University Langone Medical Center, New York., Kyriakopoulos CE; Division of Hematology, Oncology and Palliative Care, University of Wisconsin-Madison, Madison, USA., Pouessel D; Department of Medical Oncology and Clinical Research Unit, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse (IUCT-Oncopôle), Toulouse, France., Sternberg CN; Department of Genitourinary Oncology, Weill Cornell Medical College of Cornell University, New York., Tonelli J; Clinical Development - Oncology, Gilead Sciences, Inc., Parsippany., Sierecki M; Clinical Development - Oncology, Gilead Sciences, Inc., Parsippany., Zhou H; Department of Biometrics, Gilead Sciences, Inc., Foster City., Grivas P; Department of Medicine, University of Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, USA., Barthélémy P; Medical Oncology Department, Institut de Cancérologie Strasbourg Europe, Strasbourg, France., Tagawa ST; Department of Genitourinary Oncology, Weill Cornell Medical College of Cornell University, New York.
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Apr; Vol. 35 (4), pp. 392-401. Date of Electronic Publication: 2024 Jan 18.
Autor:
Matsubara N; National Cancer Center Hospital East, Chiba, Japan., de Wit R; Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Balar AV; Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Siefker-Radtke AO; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zolnierek J; LUX MED Onkologia Hospital, Warsaw, Poland., Csoszi T; Jász-Nagykun-Szolnok County Hospital, Szolnok, Hungary., Shin SJ; Yosnei University College of Medicine, Seoul, South Korea., Park SH; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Atduev V; Volga District Medical Center, Federal Medical-Biological Agency, Nizhny Novgorod, Russia., Gumus M; Istanbul Medeniyet University, Istanbul, Turkey., Su YL; Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan., Karaca SB; Tülay Aktaş Onkoloji Hastanesi, İzmir Bornova, Turkey., Cutuli HJ; Institute for Diagnosis and Metabolic Research (IDIM), Buenos Aires, Argentina., Sendur MAN; Ankara Yildirim Beyazıt University Faculty of Medicine and Ankara City Hospital, Ankara, Turkey., Shen L; Merck & Co., Inc., Rahway, NJ, USA., O'Hara K; Eisai LTD, Hatfield, UK., Okpara CE; Eisai LTD, Hatfield, UK., Franco S; Merck & Co., Inc., Rahway, NJ, USA., Moreno BH; Merck & Co., Inc., Rahway, NJ, USA., Grivas P; University of Washington, Fred Hutchinson Cancer Center, Seattle, WA, USA. Electronic address: pgrivas@uw.edu., Loriot Y; Gustave Roussy, Cancer Campus, Villejuif, France; Université Paris-Saclay, Villejuif, France. Electronic address: Yohann.loriot@gustaveroussy.fr.
Publikováno v:
European urology [Eur Urol] 2024 Mar; Vol. 85 (3), pp. 229-238. Date of Electronic Publication: 2023 Sep 29.
Autor:
Wise DR; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA. David.Wise@nyulangone.org., Pachynski RK; Division of Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA., Denmeade SR; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA., Aggarwal RR; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA., Deng J; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Febles VA; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.; New York Harbor Veterans Healthcare System, New York, NY, USA., Balar AV; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Economides MP; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Loomis C; Department of Pathology and DART Experimental Pathology Research Laboratory, NYU Langone Health, New York, NY, USA., Selvaraj S; Department of Pathology and DART Experimental Pathology Research Laboratory, NYU Langone Health, New York, NY, USA., Haas M; Leap Therapeutics, Inc, Cambridge, MA, USA., Kagey MH; Leap Therapeutics, Inc, Cambridge, MA, USA., Newman W; Leap Therapeutics, Inc, Cambridge, MA, USA., Baum J; Leap Therapeutics, Inc, Cambridge, MA, USA., Troxel AB; Division of Biostatistics, Department of Population Health at NYU Grossman School of Medicine, New York, NY, USA., Griglun S; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Leis D; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Yang N; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Aranchiy V; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Machado S; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Waalkes E; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Gargano G; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Soamchand N; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Puranik A; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.; Precision Immunology Laboratory, Perlmutter Cancer Center, NYU Langone Health, New York, NY, 10016, USA., Chattopadhyay P; Precision Immunology Laboratory, Perlmutter Cancer Center, NYU Langone Health, New York, NY, 10016, USA., Fedal E; Department of Pathology, New York University School of Medicine, New York, NY, USA., Deng FM; Department of Pathology, New York University School of Medicine, New York, NY, USA., Ren Q; Department of Pathology, New York University School of Medicine, New York, NY, USA., Chiriboga L; Department of Pathology, New York University School of Medicine, New York, NY, USA., Melamed J; Department of Pathology, New York University School of Medicine, New York, NY, USA., Sirard CA; Leap Therapeutics, Inc, Cambridge, MA, USA., Wong KK; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Publikováno v:
Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2024 Feb 10. Date of Electronic Publication: 2024 Feb 10.
Autor:
Loriot Y; Institut de Cancérologie Gustave Roussy, Villejuif, France., Kalebasty AR; University of California, Irvine, CA, USA., Fléchon A; Centre Léon Bérard, Lyon, France., Jain RK; H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA., Gupta S; Division of Oncology, Department of Medicine, University of Utah's Huntsman Cancer Institute, UT, USA., Bupathi M; Rocky Mountain Cancer Centers, Littleton, CO, USA., Beuzeboc P; Hôpital Foch, Suresnes, France., Palmbos P; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA., Balar AV; Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA., Kyriakopoulos CE; University of Wisconsin Carbone Cancer Center, Madison, WI, USA., Pouessel D; Institut Claudius Regaud/Cancer Comprehensive Center, IUCT, Oncopole, Toulouse, France., Sternberg CN; Weill Cornell Medicine, New York, NY, USA., Tonelli J; Gilead Sciences, Inc., Parsippany, NJ, USA., Sierecki M; Gilead Sciences, Inc., Parsippany, NJ, USA., Zhou H; Gilead Sciences, Inc., Parsippany, NJ, USA., Grivas P; Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA., Barthélémy P; Hôpitaux Universitaires de Strasbourg/Institut de Cancérologie Strasbourg Europe, Strasbourg, France., Bangs R; Patient Advocate, Pittsford, New York, NY, USA., Tagawa ST; Weill Cornell Medicine, New York, NY, USA.
Publikováno v:
Future oncology (London, England) [Future Oncol] 2024; Vol. 20 (23), pp. 1621-1631. Date of Electronic Publication: 2024 Jun 05.
Autor:
Adorno Febles VR; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA.; Department of Medicine, Manhattan Campus, VA NY Harbor Health Care System, New York, New York, USA., Hao Y; Applied Bioinformatics Laboratories, New York University Langone Health, New York, New York, USA., Ahsan A; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA., Wu J; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA., Qian Y; Department of Population Health, NYU Langone Health, New York, New York, USA., Zhong H; Department of Population Health, NYU Langone Health, New York, New York, USA., Loeb S; Department of Urology, New York University School of Medicine, New York, New York, USA.; Department of Urology, Manhattan Campus, VA NY Harbor Health Care System, New York, New York, USA., Makarov DV; Department of Urology, New York University School of Medicine, New York, New York, USA.; Department of Urology, Manhattan Campus, VA NY Harbor Health Care System, New York, New York, USA., Lepor H; Department of Urology, New York University School of Medicine, New York, New York, USA., Wysock J; Department of Urology, New York University School of Medicine, New York, New York, USA., Taneja SS; Department of Urology, New York University School of Medicine, New York, New York, USA., Huang WC; Department of Urology, New York University School of Medicine, New York, New York, USA., Becker DJ; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA.; Department of Medicine, Manhattan Campus, VA NY Harbor Health Care System, New York, New York, USA., Balar AV; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA., Melamed J; Department of Pathology, New York University School of Medicine, New York, New York, USA., Deng FM; Department of Pathology, New York University School of Medicine, New York, New York, USA., Ren Q; Department of Pathology, New York University School of Medicine, New York, New York, USA., Kufe D; Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Wong KK; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA., Adeegbe DO; Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA., Deng J; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA., Wise DR; Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA.
Publikováno v:
The Prostate [Prostate] 2023 Jun; Vol. 83 (9), pp. 840-849. Date of Electronic Publication: 2023 Mar 29.
Autor:
Larkin J; Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UK., Oya M; Department of Urology, Keio University Hospital, Tokyo, Japan., Martignoni M; Clinical Development and Operations, Pfizer, Milan, Italy., Thistlethwaite F; The Christie NHS Foundation Trust, Manchester, UK; Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK., Nathan P; Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK., Ornstein MC; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA., Powles T; Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew's Hospital, London, UK., Beckermann KE; Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Balar AV; Department of Medicine, Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA., McDermott D; Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA., Gupta S; Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Philips GK; Department of Medicine, Georgetown University Medical Center, Washington, DC, USA., Gordon MS; Division of Cancer Research, HonorHealth Research Institute, Scottsdale, AZ, USA., Uemura H; Department of Medicine, Kindai University Hospital, Osaka, Japan., Tomita Y; Department of Urology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan., Wang J; Biostatistics, Pfizer, Cambridge, MA, USA., Michelon E; Safety Surveillance & Risk Management, New York, NY, USA., di Pietro A; Global Product Development, Pfizer, Milan, Italy., Choueiri TK; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Publikováno v:
The oncologist [Oncologist] 2023 Apr 06; Vol. 28 (4), pp. 333-340.